Fuchs endothelial corneal dystrophy Market: Epidemiology, Therapies, Companies, DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon

Fuchs endothelial corneal dystrophy emerging therapies, such as Ripasudil (K-321), TTHX 1114, and others, are expected to boost the Fuchs endothelial corneal dystrophy Market in the upcoming years.

DelveInsight has launched a new report on "Fuchs endothelial corneal dystrophy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Fuchs endothelial corneal dystrophy, historical and forecasted epidemiology as well as the Fuchs endothelial corneal dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Fuchs endothelial corneal dystrophy market report @ https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Fuchs endothelial corneal dystrophy Market Report:

In 2023, the total market size for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets (7MM) was approximately USD 858 million, with expectations for growth by 2034. The US represented the largest share of the market, accounting for nearly USD 394 million, compared to the EU4 (Germany, Italy, France, Spain), the UK, and Japan.
Among the EU4 and the UK, Germany had the highest market size for FECD in 2023, valued at around USD 88 million, followed by Italy at approximately USD 67 million, while Spain had the smallest share with around USD 50 million.
The FECD market is expected to continue growing steadily from 2023 to 2034, driven by the introduction of new therapies. DelveInsight estimates that around 35% of the total diagnosed prevalent cases of FECD in the 7MM were in the US. In 2022, the EU4 and the UK accounted for about 9.2 million diagnosed prevalent cases of FECD.
In 2023, the United States accounted for the largest share of diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) among the seven major markets (7MM), representing around 35% of the total cases. On the other hand, Spain had the smallest share, with nearly 7% of the total diagnosed prevalent cases of FECD in the same year.
Within the EU4 and the United Kingdom, the 50 to 59 age group had the highest prevalence of FECD, with approximately 2.7 million cases reported in 2023. Projections suggest that these numbers are expected to rise during the study period from 2020 to 2034.
The FECD treatment market is also forecasted to grow with the advent of new, effective treatments such as Ripasudil/K-321, TTHX1114/NM141, and others.
In 2023, the total market size for Fuchs Endothelial Corneal Dystrophy (FECD) across the seven major markets (7MM) was approximately USD 858 million, with expectations for growth by 2034. Rising awareness of FECD is likely to expand the market in the coming years, potentially leading to an increase in the number of diagnosed cases.
Design Therapeutics is advancing its GeneTAC® small molecule eye drop, DT-168, targeting the mutant TCF4 gene associated with FECD. Positive Phase 1 trial results in healthy volunteers have been reported, with plans for a Phase 2 biomarker trial in FECD patients scheduled for the second half of 2025. If successful, DT-168 could become the first disease-modifying therapy for FECD.
A novel corneal cell therapy technique has received clinical use approval in Japan in early 2024. This therapy, which includes the implantation of cultured human endothelial cells, is currently under investigation in the U.S., with potential FDA approval anticipated around 2026 or 2027, depending on clinical trial outcomes.
Key Fuchs endothelial corneal dystrophy companies such as Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, and others are evaluating new drugs for Fuchs endothelial corneal dystrophy to improve the treatment landscape.
Promising Fuchs endothelial corneal dystrophy therapies include Ripasudil (K-321), TTHX 1114, and others.

Fuchs endothelial corneal dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive inherited condition that impacts the endothelial layer of the cornea. It is marked by symptoms such as corneal edema, the formation of guttae, decreased visual acuity, and can eventually result in corneal blindness. FECD is more prevalent in women, and its occurrence differs across regions in the seven major markets (7MM). The disease is linked to genetic factors, with mutations in genes such as COL8A2, SLC4A11, TCF4, and ZEB1 playing a role in its development.

Fuchs endothelial corneal dystrophy Market Outlook

Fuchs Endothelial Corneal Dystrophy (FECD) has a broad range of treatment options within its disease management approach. The primary treatment methods focus on the use of hyperosmotic sodium chloride, steroids, and other therapies as necessary.

Currently, the standard of care, including hyperosmotic sodium chloride and steroids, plays a significant role in generating revenue within the treatment landscape.

Discover how the Fuchs endothelial corneal dystrophy market is rising in the coming years @ https://www.delveinsight.com/sample-request/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Fuchs endothelial corneal dystrophy Emerging Drugs
Ripasudil (K-321): Kowa Pharmaceuticals
TTHX 1114: Trefoil Therapeutics

Scope of the Fuchs endothelial corneal dystrophy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fuchs endothelial corneal dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, and others
Key Fuchs endothelial corneal dystrophy Therapies: Ripasudil (K-321), TTHX 1114, and others
Fuchs endothelial corneal dystrophy Therapeutic Assessment: Fuchs endothelial corneal dystrophy current marketed and Fuchs endothelial corneal dystrophy emerging therapies
Fuchs endothelial corneal dystrophy Market Dynamics: Fuchs endothelial corneal dystrophy market drivers and Fuchs endothelial corneal dystrophy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Fuchs endothelial corneal dystrophy Unmet Needs, KOL's views, Analyst's views, Fuchs endothelial corneal dystrophy Market Access and Reimbursement

To know what's more in our Fuchs endothelial corneal dystrophy report, visit https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Fuchs endothelial corneal dystrophy Market Report:
Fuchs endothelial corneal dystrophy market report covers a descriptive overview and comprehensive insight of the Fuchs endothelial corneal dystrophy Epidemiology and Fuchs endothelial corneal dystrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Fuchs endothelial corneal dystrophy market report provides insights into the current and emerging therapies.
The Fuchs endothelial corneal dystrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Fuchs endothelial corneal dystrophy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fuchs endothelial corneal dystrophy market.

Got queries? Click here to know more about the Fuchs endothelial corneal dystrophy market Landscape https://www.delveinsight.com/sample-request/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Fuchs endothelial corneal dystrophy Patient Share (%) Overview at a Glance
5. Fuchs endothelial corneal dystrophy Market Overview at a Glance
6. Fuchs endothelial corneal dystrophy Disease Background and Overview
7. Fuchs endothelial corneal dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Fuchs endothelial corneal dystrophy
9. Fuchs endothelial corneal dystrophy Current Treatment and Medical Practices
10. Unmet Needs
11. Fuchs endothelial corneal dystrophy Emerging Therapies
12. Fuchs endothelial corneal dystrophy Market Outlook
13. Country-Wise Fuchs endothelial corneal dystrophy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Fuchs endothelial corneal dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Fuchs endothelial corneal dystrophy Market Outlook 2034 https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Fuchs endothelial corneal dystrophy Pipeline Insights, DelveInsight

"Fuchs endothelial corneal dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fuchs endothelial corneal dystrophy market. A detailed picture of the Fuchs endothelial corneal dystrophy pipeline landscape is provided, which includes the disease overview and Fuchs endothelial corneal dystrophy treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.